Q-omics provides the consensus-scored TPT1P9 profile across patient tissues and cancer cell-line models. TPT1P9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TPT1P9 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, TPT1P9 RNA expression shows 13,716 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, COAD, and ACC as cancer lineages where TPT1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPT1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPT1P9 survival associations across molecular data types. TPT1P9 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPT1P9 RNA expression–survival associations across cancer types. High TPT1P9 expression shows unfavorable associations in OV, ACC and STAD, but favorable associations in SKCM, MESO and UCEC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for TPT1P9 RNA expression.
This table summarizes TPT1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TPT1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPT1P9 shows lower tumor expression in LUSC, BLCA, KICH and BRCA and higher tumor expression in COAD and KIRC. The COAD box plot shows higher TPT1P9 RNA expression in tumor versus normal tissue (log2 FC = +1.797, t-test p < 0.001).
This table shows molecular features associated with TPT1P9 in patient tissues and cancer cell lines. In patient samples, TPT1P9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
